Lajos Pusztai
Experienced in Bone Tumor

Dr. Lajos Pusztai

Oncology
Yale University
20 York St, 
New Haven, CT 
Experienced in Bone Tumor
Yale University
20 York St, 
New Haven, CT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Lajos Pusztai is an Oncologist in New Haven, Connecticut. Dr. Pusztai is rated as an Experienced provider by MediFind in the treatment of Bone Tumor. His top areas of expertise are Triple-Negative Breast Cancer, Breast Cancer, Inflammatory Breast Cancer, HER2 Negative Breast Cancer, and Tissue Biopsy.

His clinical research consists of co-authoring 360 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Bone Tumor.

Specialties
Oncology
Licenses
Internal Medicine in TX
Hospital Affiliations
Yale-New Haven Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

YALE UNIVERSITY
20 York St, New Haven, CT 06510
Other Locations
YALE UNIVERSITY
800 Howard Ave, New Haven, CT 06519

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Gut and Intratumoral Microbiome Effect on the Neoadjuvant Chemotherapy-induced Immunosurveillance in Triple Negative Breast Cancer
Gut and Intratumoral Microbiome Effect on the Neoadjuvant Chemotherapy-induced Immunosurveillance in Triple Negative Breast Cancer
Enrollment Status: Completed
Publish Date: October 14, 2025
ISPY-P1.01: Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer: A Phase I/Ib Trial
ISPY-P1.01: Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer: A Phase I/Ib Trial
Enrollment Status: Withdrawn
Publish Date: November 18, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With Metastatic Breast Cancer
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: March 07, 2023
Intervention Type: Drug
Study Drugs: Ladiratuzumab vedotin, Trastuzumab
Study Phase: Phase 1
Single Arm Neoadjuvant Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) Concomitant With Weekly Nab-paclitaxel and Dose-dense Doxorubicin/Cyclophosphamide (ddAC) Chemotherapy for Clinical Stage I-III Triple Negative Breast Cancer
Single Arm Neoadjuvant Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) Concomitant With Weekly Nab-paclitaxel and Dose-dense Doxorubicin/Cyclophosphamide (ddAC) Chemotherapy for Clinical Stage I-III Triple Negative Breast Cancer
Enrollment Status: Completed
Publish Date: October 26, 2022
Intervention Type: Drug
Study Drugs: MEDI4736, nab-paclitaxel, ddAC chemotherapy
Study Phase: Phase 1/Phase 2
View 4 Less Clinical Trials

360 Total Publications

Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women: A Secondary Analysis of the RxPONDER Randomized Clinical Trial.
Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women: A Secondary Analysis of the RxPONDER Randomized Clinical Trial.
Journal: JAMA oncology
Published: December 11, 2025
Similar Doctors
Distinguished in Bone Tumor
Dr. Hari A. Deshpande
Interventional Cardiology | Oncology | Hematology
Distinguished in Bone Tumor
Dr. Hari A. Deshpande
Interventional Cardiology | Oncology | Hematology

Yale University

20 York St, 
New Haven, CT 
 (0.1 miles away)
203-785-4638
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Hari Deshpande is an Interventional Cardiologist and an Oncologist in New Haven, Connecticut. Dr. Deshpande is rated as a Distinguished provider by MediFind in the treatment of Bone Tumor. His top areas of expertise are Adult Soft Tissue Sarcoma, Desmoid Tumor, Liposarcoma, Alveolar Soft Part Sarcoma, and Gastrostomy.

Tony Philip
Distinguished in Bone Tumor
Dr. Tony Philip
Hematology Oncology | Oncology
Distinguished in Bone Tumor
Dr. Tony Philip
Hematology Oncology | Oncology

Northwell Health Center For Advanced Medicine, RJ Zuckerberg Cancer Center

450 Lakeville Road, Entrance B, 
Lake Success, NY 
 (55.0 miles away)
516-734-8900
Languages Spoken:
English, Malayalam
See accepted insurances
Offers Telehealth

Tony Philip is an Oncologist in Lake Success, New York. Dr. Philip is rated as a Distinguished provider by MediFind in the treatment of Bone Tumor. His top areas of expertise are Adult Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, Rhabdomyosarcoma Embryonal, and Colorectal Cancer.

Steven R. Savona
Distinguished in Bone Tumor
Dr. Steven R. Savona
Hematology | Oncology
Distinguished in Bone Tumor
Dr. Steven R. Savona
Hematology | Oncology

Northwell Health Center For Advanced Medicine, RJ Zuckerberg Cancer Center

450 Lakeville Road, Entrance B, 
Lake Success, NY 
 (55.0 miles away)
516-734-8900
Languages Spoken:
English, Italian, Mandarin, Spanish
See accepted insurances
Offers Telehealth

Steven Savona is a Hematologist and an Oncologist in Lake Success, New York. Dr. Savona is rated as an Advanced provider by MediFind in the treatment of Bone Tumor. His top areas of expertise are Malignant Peripheral Nerve Sheath Tumor, Bone Tumor, Melanoma, Thrombocytopenia, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Pusztai's expertise for a condition
ConditionClose
View All 8 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile